| |
|
|
|
|
|
|
|||
|
BRIEF REPORT
From the Centro de Investigación del
Cáncer, Instituto de Biología Molecular y Celular del
Cáncer, CSIC-Universidad de Salamanca, Campus Miguel de Unamuno,
Salamanca, Spain, and Instituto de Biología y Genética
Molecular, CSIC-Universidad de Valladolid, Spain.
The antitumor ether lipid ET-18-OCH3 promotes apoptosis
in tumor cells through intracellular activation of Fas/CD95. Results of
this study showed that ET-18-OCH3 induces cocapping of Fas and membrane rafts, specialized plasma membrane regions involved in
signaling, before the onset of apoptosis in human leukemic cells.
Patches of membrane rafts accumulated Fas clusters in leukemic cells
treated with ET-18-OCH3. Sucrose gradient centrifugation of
Triton X-100 cell lysates showed that Fas translocated into membrane
rafts following ET-18-OCH3 treatment of T-leukemic Jurkat cells. Disruption of membrane raft integrity by methyl- The plasma membrane contains microdomains named
membrane rafts, consisting of dynamic assemblies of cholesterol and
sphingolipids.1-3 The presence of saturated hydrocarbon
chains in sphingolipids allows for cholesterol to be tightly
intercalated, leading to the presence of distinct liquid-ordered
phases, membrane rafts, dispersed in the liquid-disordered matrix, and
thereby more fluid, lipid bilayer.4 One key property of
membrane rafts is that they can include or exclude proteins to varying
degrees. Membrane rafts may serve as foci for recruitment and
concentration of signaling molecules at the plasma membrane, and thus
they have been implicated in signal transduction from cell surface
receptors.3
Antitumor ether phospholipids constitute a novel class of promising
cancer chemotherapeutic drugs.5-7 The ether lipid
1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine (ET-18-OCH3; edelfosine) exerts a selective cytotoxic
action against transformed cells,5-7 and has become the
effective standard and prototype of the antitumor ether phospholipids.
Encouraging clinical research on the use of ET-18-OCH3 in
purging leukemic bone marrow prior to autologous bone marrow
transplantation has been reported.8,9 ET-18-OCH3 is a potent inducer of apoptosis in tumor cells,
especially in leukemic cells, sparing normal cells.7,10,11
Recent evidence has shown that ET-18-OCH3-induced
apoptosis is mediated by the intracellular activation of Fas/CD95 cell
death receptor, independently of its ligand FasL, leading to clustering
and subsequent capping of Fas.12 ET-18-OCH3
must be incorporated into the cell to exert its apoptotic
action,7 and the ether lipid has been reported to be
accumulated in the plasma membrane.13 Because
ET-18-OCH3 is a phospholipid and acts through plasma
membrane-related processes, involving activation of cell surface Fas
receptor, we investigated whether the Fas-mediated apoptotic effect of
ET-18-OCH3 on leukemic cells involved lipid rafts.
Cell culture and apoptosis
Apoptosis was assessed by isolation of fragmented DNA as described
previously.10,14 DNA was visualized after 1% agarose gel
electrophoresis by ethidium bromide staining. For quantitative determination of apoptosis, cells (5 × 105) were fixed
overnight in 70% ethanol at 4°C. Cells were then incubated for 1 hour with 1 mg/mL RNase A and 20 µg/mL propidium iodide at room
temperature, and analyzed with a Becton Dickinson (San Jose, CA)
FACScan flow cytometer as described previously.11 Apoptotic cells were calculated as the percentage of cells in the
sub-G1 region (hypodiploidy) in cell cycle analysis.
Confocal microscopy
Isolation of lipid rafts and Western blotting Lipid rafts were isolated by using lysis conditions and centrifugation on discontinuous sucrose gradients as previously reported.15 In brief, cells (3.5 × 107) were washed with ice-cold PBS and lysed for 30 minutes on ice in 1% Triton X-100 in TNEV buffer (10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 5 mM EDTA, 1 mM sodium orthovanadate) containing 1 mM phenylmethylsulfonyl fluoride. Cells were then homogenized with 10 strokes in a Potter-Elvehjem tissue grinder. Nuclei and cellular debris were pelleted by centrifugation at 1000 rpm for 8 minutes. Then, 1 mL cleared supernatant was mixed with 1 mL 85% sucrose in TNEV and transferred to the bottom of a Beckman 14 × 95-mm centrifuge tube. The diluted lysate was overlaid with 6 mL 35% sucrose in TNEV and finally 3.5 mL 5% sucrose in TNEV. The samples were centrifuged in an SW40 rotor at 38 000 rpm for 18 hours at 4°C in a Beckman Optima LE-80K ultracentrifuge (Beckman Instruments, Palo Alto, CA), and then 1-mL fractions were collected from the top of the gradient.To determine the location of Fas and lipid rafts in the discontinuous sucrose gradient, 20 µL of the individual fractions was subjected to sodium dodecyl sulfate-12% polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotted as described previously.15,16 After blocking for 1 hour at room temperature with 5% powdered defatted milk in TBST (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.05% Tween-20), blots were incubated with anti-Fas rabbit polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA) at a dilution of 1:500 in TBST. Antibody reactivity was monitored with biotinylated anti-rabbit IgG, using an enhanced chemiluminescence detection (ECL) system (Amersham, Buckinghamshire, United Kingdom). The location of GM1-containing lipid rafts was determined using CTx B subunit conjugated to horseradish peroxidase (Sigma) and an ECL system as described previously.15
We tested whether ET-18-OCH3 affects the distribution
of membrane rafts using the raft marker FITC-CTx. CTx B subunit binds the oligosaccharide portion of ganglioside
GM1,17 which is thought to be mainly found in
rafts.18 In unstimulated Jurkat cells, distribution of
membrane rafts appeared homogeneous (Figure
1A); however, after incubation of cells
with ET-18-OCH3 lipid rafts were redistributed in a
time-dependent way to form dense patches (Figure 1A), indicating that
membrane rafts had aggregated. Because we have recently reported that
ET-18-OCH3 induced clustering and capping of Fas in human
leukemic Jurkat cells,12 we examined whether clustering of
membrane rafts led to inclusion of Fas in the clustered rafts. As shown
in Figure 1B, FITC-CTx staining colocalized with Fas in Jurkat cells
treated with ET-18-OCH3. Untreated Jurkat cells showed an
extremely weak diffuse staining of Fas, whereas incubation of cells
with ET-18-OCH3 led to a dense patchy staining by confocal
microscopy (Figure 1B), indicating clustering of Fas and corroborating
our previous data.12 The Fas patches were colocalized with
GM1 glycosphingolipid-lipid rafts, indicating that Fas
accumulated in membrane rafts in ET-18-OCH3-treated Jurkat
cells. This coclustering of membrane rafts and Fas occurred during the
first 3 hours of ET-18-OCH3 treatment, whereas
ET-18-OCH3-induced apoptosis of Jurkat cells was observed
after 6 hours of incubation (2%, 3%, and 13% apoptotic cells after
3, 4, and 6 hours of ET-18-OCH3 treatment, respectively).
Thus, clustering of Fas-associated membrane rafts preceded triggering
of apoptosis. Similar data were obtained with HL-60 cells (data
not shown).
Because Fas labeling was negligible before treatment with
ET-18-OCH3 (Figure 1B), it was not possible to discern
whether Fas was already located in lipid rafts in untreated cells or
Fas translocated into the membrane rafts on cell treatment with the
ether lipid. To work out this issue we isolated lipid rafts in both
untreated and ET-18-OCH3-treated Jurkat cells. Lipid rafts
can be isolated based on their insolubility in Triton X-100 detergent
and buoyant density on sucrose density gradients. Thus, Jurkat cells
were lysed in 1% Triton X-100 lysis buffer and fractionated by
discontinuous sucrose gradient centrifugation as previously
described.15 The distinct fractions from the gradient were
analyzed by SDS-PAGE and Western blotting. The position of the membrane
rafts in the sucrose gradient was determined by the presence of the
ganglioside GM1, detected using the
GM1-specific ligand CTx B subunit (Figure 2). GM1 was enriched in the
upper part of the sucrose gradient (fractions 4-6), with a secondary
localization at the bottom of the gradient (fractions 10-12),
indicating a separation of the lipid rafts (fractions 4-6) from the
Triton X-100-soluble membranes (Figure 2). By Western blot analysis
using a specific anti-Fas antibody, we found that Fas was located in
the soluble fractions of the sucrose gradient (fractions 10-12) and not
in the detergent-insoluble lipid raft region in untreated Jurkat cells,
indicating that Fas is excluded from the lipid rafts in untreated
Jurkat cells (Figure 2). However, after ET-18-OCH3
treatment, a significant portion of Fas was translocated into the lipid
raft region (fractions 4-6) of the sucrose gradient (Figure 2). These
data indicate that ET-18-OCH3 treatment induces
translocation of Fas into lipid rafts.
Membrane rafts are enriched in cholesterol, and depletion of cellular
cholesterol can disrupt rafts and destroy function.3 To
explore the role of membrane rafts in ET-18-OCH3-induced
apoptosis, we disrupted membrane rafts by cell incubation with MCD or
filipin in serum-free medium. MCD specifically removes cholesterol from the plasma membrane,19,20 and filipin is a polyene
antibiotic that specifically complexes cholesterol and disrupts lipid
raft function.21,22 HL-60 cells were used in these assays
because they are prone to undergo ET-18-OCH3-induced
apoptosis and can be cultured for longer times than Jurkat cells in
serum-free medium.10,14 We found that MCD or filipin
inhibited ET-18-OCH3-induced apoptosis in leukemic HL-60
cells (Figure 3A,B), indicating that
ET-18-OCH3-induced apoptosis required membrane
raft integrity. Bone marrow cells derived from patients with
acute myeloblastic leukemia or acute promyelocytic leukemia (M2 or M3,
respectively, following the FAB classification) were positive for Fas
(> 60% positive cells), and underwent apoptosis after
ET-18-OCH3 treatment (Figure 3C), corroborating our
previous findings.7 In these M2 and M3 primary leukemic
cells, Fas was clustered on ET-18-OCH3 treatment in a similar way to that of Jurkat and HL-60 cells (data not shown), and
ET-18-OCH3-induced apoptosis of primary leukemic cells was also inhibited by MCD (Figure 3C). Furthermore, MCD-treated leukemic HL-60 cells did not show Fas clustering after ET-18-OCH3
treatment (Figure 3D).
The present findings indicate that translocation of Fas into membrane
rafts and clustering of membrane raft-associated Fas trigger the
apoptotic signaling cascade in leukemic cells treated with
ET-18-OCH3. The evidence for this conclusion is 3-fold: (1) Fas is translocated into membrane rafts following
ET-18-OCH3 treatment; (2) Fas is accumulated in aggregated
rafts on ET-18-OCH3 treatment; and (3) raft disruption
inhibits both ET-18-OCH3-induced apoptosis and Fas
clustering. Fas has been shown to be required for
ET-18-OCH3-induced apoptosis because Fas+
cells, but not Fas The data reported herein showing that Fas is translocated into rafts on ET-18-OCH3 treatment and that reorganization of membrane raft-associated Fas is required for ET-18-OCH3-induced apoptosis indicate for the first time the association of Fas with membrane rafts and that antitumor ether lipids require membrane rafts for their proapoptotic activity. Thus, the present findings involve for the first time membrane rafts in cancer chemotherapy and Fas-mediated apoptosis. The generation of stabilized membrane lipid domains from a highly dispersed distribution may represent a general mode of regulating Fas activation. Membrane rafts could serve as platforms for coupling adaptor proteins required for Fas signaling.
We thank E. Del Canto-Jañez for excellent technical assistance and S. Callejo, E. Barbosa, and M. A. Ollacarizqueta for their help in confocal microscopy. We also thank Antonio Iglesias and Manuel Modolell for helpful discussions.
Submitted April 6, 2001; accepted August 7, 2001.
Supported by grants 1FD97-0622 and 1FD97-2018-C02-01 from the European Commission and Comisión Interministerial de Ciencia y Tecnología, and grant CDTI 97-0355 from INKEYSA and Ministerio de Industria y Energía of Spain.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Faustino Mollinedo, Centro de Investigación del Cáncer, Instituto de Biología Molecular y Celular del Cáncer, CSIC-Universidad de Salamanca, Campus Miguel de Unamuno, E-37007 Salamanca, Spain; e-mail: fmollin{at}usal.es.
1. Simons K, van Meer G. Lipid sorting in epithelial cells. Biochemistry. 1988;27:6197-6202[CrossRef][Medline] [Order article via Infotrieve]. 2. Sankaram MB, Thompson TE. Interaction of cholesterol with various glycerophospholipids and sphingomyelin. Biochemistry. 1990;29:10670-10675[CrossRef][Medline] [Order article via Infotrieve]. 3. Simons K, Toomre D. Lipid rafts and signal transduction. Nature Rev. 2000;1:31-39. 4. Brown DA, London E. Functions of lipid rafts in biological membranes. Annu Rev Cell Dev Biol. 1998;14:111-136[CrossRef][Medline] [Order article via Infotrieve]. 5. Munder PG, Westphal O. Antitumoral and other biomedical activities of synthetic ether lysophospholipids. Chem Immunol. 1990;49:206-235[Medline] [Order article via Infotrieve]. 6. Houlihan W, Lohmeyer M, Workman P, Cheon SH. Phospholipid antitumor agents. Med Res Rev. 1995;15:157-223[CrossRef][Medline] [Order article via Infotrieve].
7.
Mollinedo F, Fernandez-Luna JL, Gajate C, et al.
Selective induction of apoptosis in cancer cells by the ether lipid ET-18-OCH3 (edelfosine): molecular structure requirements, cellular uptake, and protection by Bcl-2 and Bcl-xL.
Cancer Res.
1997;57:1320-1328 8. Koenigsmann MP, Notter M, Knauf WU, et al. Chemopurging of peripheral blood-derived progenitor cells by alkyl-lysophospholipid and its effect on haematopoietic rescue after high-dose therapy. Bone Marrow Transplant. 1996;18:549-557[Medline] [Order article via Infotrieve]. 9. Yamazaki T, Sieber F. The alkyl-lysophospholipid ET-18-OCH3 synergistically enhances the Merocyanine 540-mediated photoinactivation of leukemia cells: implications for the extracorporeal purging of autologous hematopoietic stem cells. Bone Marrow Transplant. 1997;19:113-119[CrossRef][Medline] [Order article via Infotrieve]. 10. Mollinedo F, Martinez-Dalmau R, Modolell M. Early and selective induction of apoptosis in human leukemic cells by the alkyl-lysophospholipid ET-18-OCH3. Biochem Biophys Res Commun. 1993;192:603-609[CrossRef][Medline] [Order article via Infotrieve]. 11. Gajate C, Santos-Beneit AM, Macho A, et al. Involvement of mitochondria and caspase-3 in ET-18-OCH3-induced apoptosis of human leukemic cells. Int J Cancer. 2000;86:208-218[CrossRef][Medline] [Order article via Infotrieve]. 12. Gajate C, Fonteriz RI, Cabaner C, et al. Intracellular triggering of Fas, independently of FasL, as a new mechanism of antitumor ether lipid-induced apoptosis. Int J Cancer. 2000;85:674-682[CrossRef][Medline] [Order article via Infotrieve]. 13. Vallari DS, Record M, Smith ZL, Snyder F. O-alkyl-O-methylglycerophosphocholine, an antineoplastic lipid, undergoes spontaneous redistribution between biological membranes prepared from HL-60 cells. Biochim Biophys Acta. 1989;1006:250-254[Medline] [Order article via Infotrieve]. 14. Mollinedo F, Santos-Beneit AM, Gajate C. The human leukemia cell line HL-60 as a cell culture model to study neutrophil functions and inflammatory responses. In: Clynes M, ed. Animal Cell Culture Techniques. Heidelberg, Germany: Springer-Verlag; 1998:264-297.
15.
Cheng PC, Dykstra ML, Mitchell RN, Pierce SK.
A role for lipid rafts in B cell antigen receptor signaling and antigen targeting.
J Exp Med.
1999;190:1549-1560
16.
Martín-Martín B, Nabokina SM, Blasi J, Lazo PA, Mollinedo F.
Involvement of SNAP-23 and syntaxin 6 in human neutrophil exocytosis.
Blood.
2000;96:2574-2583 17. Schön A, Freire E. Thermodynamics of intersubunit interactions in cholera toxin upon binding to the oligosaccharide portion of its cell surface receptor, ganglioside GM1. Biochemistry. 1989;28:5019-5024[CrossRef][Medline] [Order article via Infotrieve].
18.
Harder T, Scheiffele P, Verkade P, Simons K.
Lipid domain structure of the plasma membrane revealed by patching of membrane components.
J Cell Biol.
1998;141:929-942
19.
Neufeld EB, Cooney AD, Pitha J, et al.
Intracellular trafficking of cholesterol monitored with a cyclodextrin.
J Biol Chem.
1996;271:21604-21613 20. Christian AE, Haynes MC, Phillips MC, Rothblat GH. Use of cyclodextrins for manipulating cellular cholesterol content. J Lipid Res. 1997;38:2264-2272[Abstract]. 21. De Kruijff B, Demel RA. Polyene antibiotic-sterol interactions in membranes of Acholeplasma laidlawii cells and lecithin liposomes, 3: molecular structure of the polyene antibiotic-cholesterol complexes. Biochim Biophys Acta. 1974;339:57-70[Medline] [Order article via Infotrieve].
22.
Orlandi PA, Fishman PH.
Filipin-dependent inhibition of cholera toxin: evidence for toxin internalization and activation through caveolae-like domains.
J Cell Biol.
1998;141:905-915 23. Moran M, Miceli MC. Engagement of GPI-linked CD48 contributes to TCR signals and cytoskeletal reorganization: a role for lipid rafts in T cell activation. Immunity. 1998;9:787-796[CrossRef][Medline] [Order article via Infotrieve]. 24. Parlato S, Giammarioli AM, Logozzi M, et al. CD95 (APO-1/Fas) linkage to the actin cytoskeleton through ezrin in human T lymphocytes: a novel regulatory mechanism of the CD95 apoptotic pathway. EMBO J. 2000;19:5123-5134[CrossRef][Medline] [Order article via Infotrieve]. 25. Diomede L, Bizzi A, Magistrelli A, Modest EJ, Salmona M, Noseda A. Role of cell cholesterol in modulating antineoplastic ether lipid uptake, membrane effects and cytotoxicity. Int J Cancer. 1990;46:341-346[Medline] [Order article via Infotrieve].
© 2001 by The American Society of Hematology.
| ||||||||||
![]() |
C. S. Mitsiades, E. M. Ocio, A. Pandiella, P. Maiso, C. Gajate, M. Garayoa, D. Vilanova, J. C. Montero, N. Mitsiades, C. J. McMullan, et al. Aplidin, a Marine Organism-Derived Compound with Potent Antimyeloma Activity In vitro and In vivo Cancer Res., July 1, 2008; 68(13): 5216 - 5225. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Beneteau, M. Pizon, B. Chaigne-Delalande, S. Daburon, P. Moreau, F. De Giorgi, F. Ichas, A. Rebillard, M.-T. Dimanche-Boitrel, J.-L. Taupin, et al. Localization of Fas/CD95 into the Lipid Rafts on Down-Modulation of the Phosphatidylinositol 3-Kinase Signaling Pathway Mol. Cancer Res., April 1, 2008; 6(4): 604 - 613. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Sharif-Askari, D. Gaucher, R. Halwani, J. Ma, K. Jao, A. Abdallah, E. K. Haddad, and R.-P. Sekaly p56Lck Tyrosine Kinase Enhances the Assembly of Death-inducing Signaling Complex during Fas-mediated Apoptosis J. Biol. Chem., December 7, 2007; 282(49): 36048 - 36056. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Nieto-Miguel, R. I. Fonteriz, L. Vay, C. Gajate, S. Lopez-Hernandez, and F. Mollinedo Endoplasmic Reticulum Stress in the Proapoptotic Action of Edelfosine in Solid Tumor Cells Cancer Res., November 1, 2007; 67(21): 10368 - 10378. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Kim, T. R. Chaudhuri, D. J. Buchsbaum, D. Wang, and K. R. Zinn High-resolution single-photon emission computed tomography and X-ray computed tomography imaging of Tc-99m-labeled anti-DR5 antibody in breast tumor xenografts Mol. Cancer Ther., March 1, 2007; 6(3): 866 - 875. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Gajate and F. Mollinedo Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts Blood, January 15, 2007; 109(2): 711 - 719. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Nieto-Miguel, C. Gajate, and F. Mollinedo Differential Targets and Subcellular Localization of Antitumor Alkyl-lysophospholipid in Leukemic Versus Solid Tumor Cells J. Biol. Chem., May 26, 2006; 281(21): 14833 - 14840. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Nachbur, D. Kassahn, S. Yousefi, D. F. Legler, and T. Brunner Posttranscriptional regulation of Fas (CD95) ligand killing activity by lipid rafts Blood, April 1, 2006; 107(7): 2790 - 2796. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Mandal, A. Mazumder, P. Das, M. Kundu, and J. Basu Fas-, Caspase 8-, and Caspase 3-dependent Signaling Regulates the Activity of the Aminophospholipid Translocase and Phosphatidylserine Externalization in Human Erythrocytes J. Biol. Chem., November 25, 2005; 280(47): 39460 - 39467. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Zaremberg, C. Gajate, L. M. Cacharro, F. Mollinedo, and C. R. McMaster Cytotoxicity of an Anti-cancer Lysophospholipid through Selective Modification of Lipid Raft Composition J. Biol. Chem., November 11, 2005; 280(45): 38047 - 38058. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Fotin-Mleczek, S. Welte, O. Mader, F. Duchardt, R. Fischer, H. Hufnagel, P. Scheurich, and R. Brock Cationic cell-penetrating peptides interfere with TNF signalling by induction of TNF receptor internalization J. Cell Sci., August 1, 2005; 118(15): 3339 - 3351. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Rotolo, J. Zhang, M. Donepudi, H. Lee, Z. Fuks, and R. Kolesnick Caspase-dependent and -independent Activation of Acid Sphingomyelinase Signaling J. Biol. Chem., July 15, 2005; 280(28): 26425 - 26434. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. S. Soderstrom, S. D. Nyberg, and J. E. Eriksson CD95 capping is ROCK-dependent and dispensable for apoptosis J. Cell Sci., May 15, 2005; 118(10): 2211 - 2223. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Bari, N. Battista, F. Fezza, A. Finazzi-Agro, and M. Maccarrone Lipid Rafts Control Signaling of Type-1 Cannabinoid Receptors in Neuronal Cells: IMPLICATIONS FOR ANANDAMIDE-INDUCED APOPTOSIS J. Biol. Chem., April 1, 2005; 280(13): 12212 - 12220. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Gajate and F. Mollinedo Cytoskeleton-mediated Death Receptor and Ligand Concentration in Lipid Rafts Forms Apoptosis-promoting Clusters in Cancer Chemotherapy J. Biol. Chem., March 25, 2005; 280(12): 11641 - 11647. [Abstract] [Full Text] [PDF] |
||||
![]() |
|